High CD8+ tumour-infiltrating lymphocyte density associates with unfavourable prognosis in oesophageal adenocarcinoma following poor response to neoadjuvant chemoradiotherapy

Histopathology. 2021 Aug;79(2):238-251. doi: 10.1111/his.14361. Epub 2021 Apr 27.

Abstract

Aims: Determining prognosis following poor response to neoadjuvant chemoradiotherapy (nCRT) in oesophageal adenocarcinoma (OAC) remains challenging. An immunosuppressive tumour microenvironment (TME) as well as immune infiltrate density and composition are considered to play a critical role in the immune interaction between host and tumour and can predict therapy response and survival in many cancers, including gastrointestinal malignancies. The aim of this study was to establish the TME characteristics associated with survival following a poor response to nCRT.

Methods and results: The prognostic significance of OAC-associated CD3+ , CD4+ , CD8+ , forkhead box protein 3 (FoxP3+ ) and programmed cell death ligand 1 (PD-L1) expression was studied by immunohistochemistry and quantified by automated image analysis in 123 patients who underwent nCRT and curative resection. Results from good and poor responders were contrasted and immune infiltration was related to disease course in both groups. Subsequently a cohort of 57 patients with a moderate response to nCRT was analysed in a similar fashion. Tumour cell percentage positively correlated to immune infiltration markers. In good and moderate responders, none of the immune infiltrate parameters was associated with survival; in poor responders CD8+ was an independent negative predictor of OS in univariate analysis (P = 0.03) and high CD8+ infiltration was associated with worse OS (15 versus 32 months, P = 0.042).

Conclusion: A high CD8+ density is an independent biomarker of poor OS in poor responders to nCRT, but not in good and moderate responders. Our results suggest that patients with a poor response to nCRT but concomitant high CD8+ counts in the resection specimen require adjuvant therapy.

Keywords: immunotherapy; neoadjuvant chemoradiotherapy; oesophageal adenocarcinoma; tumour microenvironment.

MeSH terms

  • Adenocarcinoma / immunology
  • Adenocarcinoma / pathology*
  • Adenocarcinoma / therapy*
  • Adult
  • Aged
  • Aged, 80 and over
  • B7-H1 Antigen / immunology
  • CD3 Complex / immunology
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / pathology
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / pathology*
  • Chemoradiotherapy*
  • Cohort Studies
  • Esophageal Neoplasms / immunology
  • Esophageal Neoplasms / pathology*
  • Esophageal Neoplasms / therapy*
  • Female
  • Forkhead Transcription Factors / immunology
  • Humans
  • Image Processing, Computer-Assisted
  • Immunohistochemistry
  • Lymphocytes, Tumor-Infiltrating / immunology*
  • Lymphocytes, Tumor-Infiltrating / pathology*
  • Male
  • Middle Aged
  • Neoadjuvant Therapy*
  • Prognosis
  • Treatment Outcome
  • Tumor Microenvironment / immunology

Substances

  • B7-H1 Antigen
  • CD3 Complex
  • FOXP3 protein, human
  • Forkhead Transcription Factors

Supplementary concepts

  • Adenocarcinoma Of Esophagus